Arrowstreet Capital’s Ascendis Pharma A/S ASND Stock Holding History

Arrowstreet Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.9M	Buy	+91,470	New	+$20.5M	0.01%	739
2025 Q4	–	Sell	-60,658	Closed	-$12.1M	–	1828
2025 Q3	$12.1M	Buy	+60,658	New	+$11.3M	0.01%	901
2023 Q1	–	Sell	-29,218	Closed	-$3.57M	–	1342
2022 Q4	$3.57M	Buy	+29,218	New	+$3.39M	0.01%	753
2022 Q3	–	Sell	-13,105	Closed	-$1.22M	–	1262
2022 Q2	$1.22M	Buy	13,105 +11,085	+549%	+$1.04M	﹤0.01%	892
2022 Q1	$237K	Buy	+2,020	New	+$234K	﹤0.01%	1106
2020 Q2	–	Sell	-3,500	Closed	-$394K	–	2284
2020 Q1	$394K	Buy	+3,500	New	+$455K	﹤0.01%	1575
2019 Q4	–	Sell	-13,700	Closed	-$1.32M	–	1723
2019 Q3	$1.32M	Buy	+13,700	New	+$1.53M	﹤0.01%	1094
2019 Q1	–	Sell	-25,799	Closed	-$1.62M	–	1714
2018 Q4	$1.62M	Buy	25,799 +5,484	+27%	+$345K	﹤0.01%	853
2018 Q3	$1.44M	Sell	20,315 -8,637	-30%	-$595K	﹤0.01%	732
2018 Q2	$1.93M	Buy	+28,952	New	+$1.9M	﹤0.01%	696

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Arrowstreet Capital's ASND Position: Q1 2026 in Review

Arrowstreet Capital opened a new position in Ascendis Pharma A/S (ASND) in Q1 2026: 91,470 shares worth $20.9M. The stake represents 0.01% of the portfolio and ranks #739 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in ASND as recently as Q3 2025.

Arrowstreet Capital first reported a position in ASND in Q2 2018 and has held it in 10 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Arrowstreet Capital held 91,470 shares of Ascendis Pharma A/S worth $20.9M as of Q1 2026.
Ascendis Pharma A/S was a new Arrowstreet Capital position in Q1 2026.
Ascendis Pharma A/S made up 0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #739 holding.
Arrowstreet Capital first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 10 quarters since.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.